nsc 664704 has been researched along with Brain Neoplasms in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kitabayashi, T | 1 |
Dong, Y | 1 |
Furuta, T | 1 |
Sabit, H | 1 |
Jiapaer, S | 1 |
Zhang, J | 1 |
Zhang, G | 1 |
Hayashi, Y | 1 |
Kobayashi, M | 1 |
Domoto, T | 1 |
Minamoto, T | 1 |
Hirao, A | 1 |
Nakada, M | 1 |
1 other study available for nsc 664704 and Brain Neoplasms
Article | Year |
---|---|
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |